Fair Value Calculator Fair Value Calculator
EN DE

Cowealth Medical Holding (4745) Fair Value & Analysis

Healthcare · TW · Market cap 1,000M TWD

CM Cowealth Medical Holding 4745 · TWO
Price14.60 TWD
Fair Value14.28 TWD
Upside-2.2%
Quality36/100
Watch Cowealth Medical Holding for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range 14.23 TWD – 14.35 TWD

Fair value as of: Jul 11, 2026

From 8 valuation models · updated today

Fair value updated Jul 11, 2026 — revised from 195.04 TWD to 14.28 TWD (−92.7%) since Jun 24, 2026. Share price −7.0% over the past month.

Price vs Fair Value (12 months)

26.85 TWD 13.70 TWD Fair Value 14.28 TWD Jun 2025 Jul 2026

12‑month range 13.70 TWD – 26.85 TWD · fair‑value band 14.23 TWD – 14.35 TWD · the 14.60 TWD price screens above the 14.28 TWD fair value. As of Jul 11, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Cowealth Medical Holding (4745) currently trades at 14.60 TWD, while our model-based Fair Value estimate is 14.28 TWD — implying the stock looks roughly 2.2% overvalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, Cowealth Medical Holding generated revenue of 2.9B TWD at a net margin of -8.6%. Revenue declined 11.6% year over year. It earns a return on equity of -6.5%. Net debt stands at 60.9M TWD. Fundamentals as of Jul 11, 2026

Our scenario range runs from 14.23 TWD (bear case) to 14.35 TWD (bull case); at 14.60 TWD, the current price sits above that range. The share trades about 47% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -29% fair-value upside — at -2%, 4745 screens cheaper than that median.

Key figures & financial health

Revenue (TTM) 2.9B TWD
Revenue growth (YoY) -11.6%
Net margin -8.6%
Return on equity -6.5%
Free cash flow 836K TWD FY2025
Operating margin -8.0%
More key figures
EPS (TTM) -3.18 TWD
EPS growth (YoY) -80.6%
Net debt 60.9M TWD FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 11, 2026. TTM = trailing twelve months.

About the company

Cowealth Medical Holding Co., Ltd., together with its subsidiaries, engages in trading of medical equipment, reagents, and spare parts in Taiwan, China, and Hong Kong. It operates in two segments, Sells Equipment, and Sells Reagents and Others. The company also offers acme empowerment program, including al-assisted clinical decision support system, platform of management analysis and decision making, multi-channel coaxial-time-audio-video-image digital platform for operating rooms, and cross-trait medical resource platform. In addition, it provides equipment comprising CyberKnife Stereotactic Radiosurgery System, a non-invasive treatment alternative for cancerous and non-cancerous tumors, as well as other medical conditions requiring radiation therapy; LipiView Ocular Surface Interferometer and LipiView Thermal Pulsation System, a system designed to diagnose and address meibomian gland dysfunction; and MRIdian-Linac, an MRI-guided radiation therapy system. Further, the company is …

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Cowealth Medical Holding reported revenue of 3.0B TWD in FY2025 versus 5.1B TWD in FY2021, a compound −12.9%/yr. Reported net income was −247M TWD in FY2025.

Revenue −12.9%/yr
FY21 5.1B TWD
FY22 5.6B TWD
FY23 4.8B TWD
FY24 4.2B TWD
FY25 3.0B TWD
Net income
FY21 139M TWD
FY22 94.1M TWD
FY23 55.7M TWD
FY24 629K TWD
FY25 −247M TWD

Is 4745 fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "Cowealth Medical Holding Fair Value". https://www.fairvalue-calculator.com/stock/4745

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT 1,600 MXN 82.40 MXN -95%
Stryker Corporation S1YK34 R$79.21 R$43.74 -45%
Medtronic plc MDT $79.27 $73.33 -7%
Boston Scientific Corporation B1SX34 R$229.30 R$43.33 -81%
Edwards Lifesciences Corporation EW $85.98 $41.02 -52%
Siemens Healthineers AG SEMHF $40.29 $47.96 +19%
GE HealthCare Technologies Inc GEHC $63.76 $44.97 -29%
DexCom, Inc DXCM $69.07 $65.56 -5%
Koninklijke Philips N.V 1PHIA €24.31 €9.97 -59%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥141.85 ¥147.63 +4%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Cowealth Medical Holding (4745) undervalued?
As of Jul 11, 2026, our model estimates a fair value of 14.28 TWD versus a price of 14.60 TWD — about −2% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 4745?
Our model-based fair value for Cowealth Medical Holding is 14.28 TWD (as of Jul 11, 2026), built from audited fundamentals. The current price is 14.60 TWD.
What is the quality score of 4745?
Cowealth Medical Holding has a Quality Score of 36/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Cowealth Medical Holding (4745)?
Cowealth Medical Holding reported trailing-twelve-month revenue of about 2.9B TWD (latest available figure, as of Jul 11, 2026).
What is the net profit margin of 4745?
The net profit margin of Cowealth Medical Holding is about -8.6%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

The 25 strongest value stocks, free every month

Enter your email to get the free monthly Top-25 report of the most undervalued quality stocks from 35,000+ analysed. Unsubscribe anytime.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.